Market Place
Sourcing Support
Puma Biotech Initiates ALISCA™-Breast1 Phase II Trial of Alisertib
20 Nov 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Q3 2024 Financial Results
07 Nov 2024 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
BUSINESSWIRE
Puma Biotechnology To Host Q3 Results Conference Call
24 Oct 2024 //
BUSINESSWIRE
Puma Biotechnology to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
06 Aug 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Second Quarter Financial Results
01 Aug 2024 //
BUSINESSWIRE
Puma Biotechnology Schedules Q2 2024 Financial Results Call
18 Jul 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Rule 5635(c)(4)
02 Jul 2024 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Puma`s Alisertib Phase 1/1b Data In Advanced EGFR-Mutant Lung Cancer
03 Jun 2024 //
BUSINESSWIRE
Puma`s Alisertib Shows Findings In Endocrine-Resistant Metastatic Breast Cancer
02 Jun 2024 //
BUSINESSWIRE
Puma Biotechnology to Join Russell 3000 Index
28 May 2024 //
BUSINESSWIRE
Puma Alisertib Asco Abstracts: 2024 Annual Meeting Titles Published
23 May 2024 //
BUSINESSWIRE
Pfizer wins $107.5M from AZ in US cancer drug patent trial
18 May 2024 //
REUTERS
Puma Biotechnology Reports First Quarter Financial Results
02 May 2024 //
BUSINESSWIRE
Puma Biotech Q1 2024 results call
18 Apr 2024 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
BUSINESSWIRE
Puma Announces FDA Allowance to Proceed Under IND for Alisertib in Breast Cancer
20 Mar 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
27 Feb 2024 //
BUSINESSWIRE
Puma Bio to Participate in Panel Discussion at TD Cowen’s 44th Annual Conference
22 Feb 2024 //
BUSINESSWIRE
Puma to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
15 Feb 2024 //
PRESS RELEASE
Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib
13 Feb 2024 //
BUSINESSWIRE
Puma Bio to Present at B. Riley Securities 4th Annual Oncology Conference
11 Jan 2024 //
BUSINESSWIRE
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib
11 Dec 2023 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Puma Bio to Host Conference Call to Discuss Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
Puma Announces Presentation of Findings from a Phase I/II Study of Alisertib
14 Oct 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2023 //
BUSINESSWIRE
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib
21 Sep 2023 //
BUSINESSWIRE
Puma Biotechnology to Present at the H.C. Wainwright 25th Conference
31 Aug 2023 //
BUSINESSWIRE
Puma Bio Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
08 Aug 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Second Quarter Financial Results
03 Aug 2023 //
BUSINESSWIRE
Puma Bio to Host Conference to Discuss Second Quarter 2023 Financial Results
20 Jul 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Jun 2023 //
BUSINESSWIRE
Puma Announces Presentation of Biomarker Findings from PII Study of Alisertib
04 Jun 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
05 May 2023 //
BUSINESSWIRE
Puma Biotechnology Reports First Quarter Financial Results
04 May 2023 //
BUSINESSWIRE
Puma Biotechnology to Host Conference Call to Discuss 1Q 2023 Financial Results
20 Apr 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 Apr 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
02 Mar 2023 //
BUSINESSWIRE
Puma to Participate in a Panel Discussion at Annual Health Care Conference
28 Feb 2023 //
BUSINESSWIRE
Puma Biotechnology to Discuss Fourth Quarter 2022 Financial Results
16 Feb 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 Feb 2023 //
BUSINESSWIRE
Puma Biotechnology’s NERLYNX Included in NCCN Clinical Practice Guidelines
01 Feb 2023 //
BUSINESSWIRE
Puma Biotech to Present at B. Riley Securities’ 3rd Annual Oncology Conference
12 Jan 2023 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 Jan 2023 //
BUSINESSWIRE
Puma Biotechnology Releases Updated Corporate Presentation
09 Jan 2023 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
07 Dec 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635
02 Nov 2022 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the PII Trial of Neratinib
27 Oct 2022 //
BUSINESSWIRE
Puma Bio to Host Conference Call to Discuss Third Quarter Financial Results
20 Oct 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2022 //
BUSINESSWIRE
Puma Announces Agreement with Takeda for the Development of Alisertib
21 Sep 2022 //
BUSINESSWIRE
Puma Presents Findings from the PII SUMMIT Basket Trial of Neratinib
11 Sep 2022 //
BUSINESSWIRE
Puma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 Sep 2022 //
BUSINESSWIRE
